Robin A. Felder

Dr. Robin A. Felder

Department of Pathology, University of Virginia, Charlottesville, VA 22903, USA
orcid

Research Focus & Metrics

Academic Career Length

41Years (1986-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
19 March 2002 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Closed access
PDF file
Robin A. FelderRobin A. Felder
Robin A. Felder
HSHironobu Sanada
Hironobu Sanada
JXJing Xu
Jing Xu
PYPei-Ying Yu
Pei-Ying Yu
ZWZheng Wang
Zheng Wang
PJPedro A. Jose
Pedro A. Jose
Essential hypertension has a heritability as high as 30–50%, but its genetic cause(s) has not been determined despite intensive investigation. The renal dopaminergic system exerts a pivotal role in maintaining fluid and electrolyte balance and participates in the pathogenesis of genetic hypertension. In genetic hypertension, the ability of dopamine and D 1 -like agonists to increase urinary sodium excretion is impaired. A defective coupling between the D 1 dopamine receptor and the G protein/effector enzyme complex in the proximal tubule of the kidney is the cause of the impaired renal dopaminergic action in genetic rodent and human essential hypertension. We now report that, in human essential hypertension, single nucleotide polymorphisms of a G protein-coupled receptor kinase, GRK4 γ, increase G protein-coupled receptor kinase (GRK) activity and cause the serine phosphorylation and uncoupling of the D 1 receptor from its G protein/effector enzyme complex in the renal proximal tubule and in transfected Chinese hamster ovary cells. Moreover, expressing GRK4 γ A142V but not the wild-type gene in transgenic mice produces hypertension and impairs the diuretic and natriuretic but not the hypotensive effects of D 1 -like agonist stimulation. These findings provide a mechanism for the D 1 receptor coupling defect in the kidney and may explain the inability of the kidney to properly excrete sodium in genetic hypertension.

1 October 2014 in Clinical Biochemistry
Verified
Journal Article
Closed access
JGJohn J. Gildea
John J. Gildea
JSJoscelyn E. Seaton
Joscelyn E. Seaton
KVKen G. Victor
Ken G. Victor
CRCamellia M. Reyes
Camellia M. Reyes
DWDora Bigler Wang
Dora Bigler Wang
Robin A. FelderRobin A. Felder
Robin A. Felder

1 April 1999 in Hypertension
Verified
Journal Article
Open access
PDF file
HSHironobu Sanada
Hironobu Sanada
PJPedro A. Jose
Pedro A. Jose
DHDebra Hazen-Martin
Debra Hazen-Martin
PYPei-Ying Yu
Pei-Ying Yu
JXJing Xu
Jing Xu
Robin A. FelderRobin A. Felder
Robin A. Felder
—The ability of the dopamine-1 (D 1 )-like receptor to stimulate adenylyl cyclase (AC) and phospholipase C (PLC), inhibit sodium transport in the renal proximal tubule (RPT), and produce natriuresis is attenuated in several rat models of hypertension. Since the inhibitory effect of D 1 -like receptors on RPT sodium transport is also reduced in some patients with essential hypertension, we measured D 1 -like receptor coupling to AC and PLC in cultures of human RPT cells from normotensive (NT) and hypertensive (HT) subjects. Basal cAMP concentrations were the same in NT (n=6) and HT (n=4). However, the D 1 -like receptor agonist fenoldopam increased cAMP production to a greater extent in NT (maximum response=67±1%) than in HT (maximum response=17±5%), with a potency ratio of 105. Dopamine also increased cAMP production to a greater extent in NT (32±3%) than in HT (14±3%). The fenoldopam-mediated increase in cAMP production was blocked by SCH23390 (a D 1 -like receptor antagonist) and by antisense D 1 oligonucleotides in both HT and NT, indicating action at the D 1 receptor. The stimulatory effects of forskolin and parathyroid hormone–related protein of cAMP accumulation were not statistically different in NT and HT, indicating receptor specificity and an intact G-protein/AC pathway. The fenoldopam-stimulated PLC activity was not impaired in HT, and the primary sequence and expression of the D 1 receptor were the same in NT and HT. However, D 1 receptor serine phosphorylation in the basal state was greater in HT than in NT and was not responsive to fenoldopam stimulation in HT. These studies demonstrate the expression of D 1 receptors in human RPT cells in culture. The uncoupling of the D 1 receptor in both rats (previously described) and humans (described here) suggests that this mechanism may be involved in the pathogenesis of hypertension; the uncoupling may be due to ligand-independent phosphorylation of the D 1 receptor in hypertension.

1 September 2002 in Kidney International
Verified
Journal Article
Closed access
HWHidetsuna Watanabe
Hidetsuna Watanabe
JXJing Xu
Jing Xu
CBChikh Bengra
Chikh Bengra
PJPedro A. Jose
Pedro A. Jose
Robin A. FelderRobin A. Felder
Robin A. Felder

1 December 2002 in Clinical Chemistry
Verified
Journal Article
Open access
PDF file
CBChikh Bengra
Chikh Bengra
TMTheodore E Mifflin
Theodore E Mifflin
YKYuri Khripin
Yuri Khripin
PMPaolo Manunta
Paolo Manunta
SWScott M Williams
Scott M Williams
Robin A. FelderRobin A. Felder
Robin A. Felder
Background: Human hypertension is a complex, multifactorial disease with a heritability of more than 30–50%. A genetic screening test based on analysis of multiple single-nucleotide polymorphisms (SNPs) to assess the likelihood of developing hypertension would be helpful for disease management. Methods: Tailed allele-specific primers were designed to amplify by PCR six biallelic SNP loci [three in G protein-coupled receptor kinase type 4 (GRK4): R65L, A142V, and A486V; two in angiotensinogen: −6G→A and M235T; and one in aldosterone synthase: −344C→T] associated with essential hypertension. PCRs of SNP loci were coupled (via a common sequence of 21 nucleotide tails) to incorporate Universal Amplifluor™ primers labeled with fluorescein or sulforhodamine in a homogeneous format. Use of Amplifluors in SNP PCRs produced labeled amplicons, the fluorescence of which was quantified by a microplate reader and then analyzed via an Excel macro to provide genotypes for all six SNP loci. Unique restriction endonucleases were identified for five SNP loci that could independently confirm homogeneous PCR results when needed. Results: We developed six homogeneous PCR assays that were set up, performed, and fluorometrically analyzed in 96-well microplates. Allele frequencies were determined for six SNPs in 60 Italian hypertensive patients and a control group of 60 normotensive persons. A significant correlation (P = 0.034) between one SNP [GRK4 (A486V)] and the hypertensive patients was observed. Genotyping results for five of six SNPs were confirmed by digesting corresponding amplicons with locus-specific restriction endonucleases. Conclusions: We developed a simple and homogeneous fluorescent protocol that has been used to determine the SNP genotype for six loci in a population of hypertensive and normotensive persons. We also observed a significant association (P = 0.034) between one SNP (A486V) and an Italian population of mildly hypertensive patients.

1 November 2006 in Nature Clinical Practice Nephrology
Verified
Journal Article
Closed access
Robin A. FelderRobin A. Felder
Robin A. Felder
PJPedro A Jose
Pedro A Jose